Vancouver, British Columbia, October 20, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing technologies is pleased to announce that it has made first commercial delivery of its new breath-based multi-drug test panel. The panel is modeled after the drug classes included in the U.S. Department of Transportation's (DOT) federally mandated urine drug testing program, including amphetamines/methamphetamines, cocaine, marijuana (THC), opiates, and phencyclidine (PCP) (the "DOT-like Panel").
This first deployment follows the validation by Omega Laboratories, Inc. of a laboratory developed test method utilizing the Cannabix Breath Collection Unit ("BCU") and Breath Cartridge technologies. The validated method supports the simultaneous detection of multiple drug classes from breath samples, expanding Cannabix's breath testing capabilities beyond cannabinoids and demonstrating the versatility of its technology.
Unlike urine and hair testing, which can identify historical drug exposure over days, weeks, or months, employers and other decision-makers are often seeking information about more recent drug use. Breath testing is intended to target a substantially shorter detection window following drug consumption. Cannabix's breath-testing technology is designed to help address this gap by focusing on a shorter detection period, ranging from 15 minutes to 4 hours after use, which provides a more relevant time window in safety-sensitive situations. By combining observed breath collection, chain-of-custody procedures, split-sample capability, and laboratory mass spectrometry confirmation, the Company's breath-based DOT-like testing model is designed to support drug testing programs where scientific rigor, evidentiary defensibility, and operational practicality are important requirements.
The Company's new breath-based multi-drug test panel option expands Cannabix's breath-testing platform beyond marijuana detection and is targeted toward workplace testing, criminal justice and treatment monitoring programs, post-incident investigations, reasonable-suspicion testing, and other safety-sensitive environments where recent-use assessment is a key objective.
